Reuters logo
BRIEF-Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease
February 8, 2017 / 11:41 PM / 10 months ago

BRIEF-Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease

Feb 8 (Reuters) - Jazz Pharmaceuticals Plc

* Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson’s disease

* Jazz Pharmaceuticals Plc- Study is expected to enroll approximately 50 patients for phase 2 clinical study evaluating JZP-110 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below